Ponesimod, a selective sphingosine 1-phosphate (S1P₁) receptor modulator for autoimmune diseases: review of clinical pharmacokinetics and drug disposition

References

• Anderson BJ, Holford NH. (2008). Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 48:303–32
   PubMed Web of Science ®Google Scholar
• Aversa M, Porter S, Granton J. (2015). Comparative safety and tolerability of endothelin receptor antagonists in pulmonary arterial hypertension. Drug Saf 38:419–35
   PubMed Web of Science ®Google Scholar
• Boehler M, Juif PE, Hoch M, et al. (2017). Absolute bioavailability of ponesimod, a selective S1P1 receptor modulator, in healthy male subjects. Eur J Drug Metab Pharmacokinet 42:129–34
   PubMed Web of Science ®Google Scholar
• Brossard P, Derendorf H, Xu J, et al. (2013). Pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator, in the first-in-human study. Br J Clin Pharmacol 76:888–96
   PubMed Web of Science ®Google Scholar
• Brossard P, Scherz M, Halabi A, et al. (2014). Multiple-dose tolerability, pharmacokinetics, and pharmacodynamics of ponesimod, an S1P1 receptor modulator: favourable impact of dose up-titration. J Clin Pharmacol 54:179–88
   PubMed Web of Science ®Google Scholar
• Candelore MR, Wright MJ, Tota LM, et al. (2002). Phytosphingosine 1-phosphate: a high affinity ligand for the S1P(4)/Edg-6 receptor. Biochem Biophys Res Commun 297:600–6
   PubMed Web of Science ®Google Scholar
• Clair T, Aoki J, Koh E, et al. (2003). Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res 63:5446–453
   PubMed Web of Science ®Google Scholar
• D'Ambrosio D, Freedman MS, Prinz J. (2016). Ponesimod, a selective S1P1 receptor modulator: a potential treatment for multiple sclerosis and other immune-mediated diseases. Ther Adv Chronic Dis 7:18–33
   PubMed Web of Science ®Google Scholar
• David OJ, Pryce M, Meiser K, et al. (2015). Pharmacokinetics of fingolimod and metabolites in subjects with severe renal impairment: An open-label, single-dose, parallel-group study. Int J Clin Pharmacol Ther 53:847–54
   PubMed Web of Science ®Google Scholar
• Gonzalez-Cabrera PJ, Brown S, Studer SM, et al. (2014). S1P signaling: new therapies and opportunities. F1000Prime Rep 6:109
   PubMedGoogle Scholar
• Guérard N, Zwingelstein C, Hoch M, et al. (2016). Effect of hepatic or renal impairment on the pharmacokinetics, safety, and tolerability of ponesimod, a selective S1P1 receptor modulator. Basic Clin Pharmacol Toxicol 118:356–68
   PubMed Web of Science ®Google Scholar
• Guerrero M, Urbano M, Roberts E. (2016). Sphingosine 1-phosphate receptor 1 agonists: a patent review (2013-2015). Expert Opin Ther Pat 26:455–70
   PubMed Web of Science ®Google Scholar
• Hoch M, D'ambrosio D, Wilbraham D, et al. (2014). Clinical pharmacology of ponesimod, a selective S1P1 receptor modulator, after uptitration to supratherapeutic doses in healthy subjects. Eur J Pharm Sci 63:147–53
   PubMed Web of Science ®Google Scholar
• Hoch M, Darpo B, Brossard P, et al. (2015). Effect of ponesimod, a selective S1P1 receptor modulator, on the QT interval in healthy individuals. Basic Clin Pharmacol Toxicol 116:429–37. https://www.novartis.com/news/media-releases/novartis-announces-positive-phase-iii-results-showing-efficacy-baf312-patients [last accessed 2 March 2017]
   PubMed Web of Science ®Google Scholar
• Juif PE, Hoch M, D'Ambrosio D, et al. (2015). Biocomparison of three formulations of the S1P1 receptor modulator ponesimod in healthy subjects. Drugs R D 15:203–10
   PubMed Web of Science ®Google Scholar
• Kovarik JM, Slade A, Voss B, et al. (2007). Ethnic sensitivity study of fingolimod in White and Asian subjects. Int J Clin Pharmacol Ther 45:98–109
   PubMed Web of Science ®Google Scholar
• Krause A, Brossard P, D'Ambrosio D, et al. (2014). Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator. J Pharmacokinet Pharmacodyn 41:261–78
   PubMed Web of Science ®Google Scholar
• Krösser S, Wolna P, Fischer TZ, et al. (2015). Effect of ceralifimod (ONO-4641) on lymphocytes and cardiac function: Randomized, double-blind, placebo-controlled trial with an open-label fingolimod arm. J Clin Pharmacol 55:1051–60
   PubMed Web of Science ®Google Scholar
• Liang J, Nagahashi M, Kim EY, et al. (2013). Sphingosine-1-phosphate links persistent STAT3 activation, chronic intestinal inflammation, and development of colitis-associated cancer. Cancer Cell 23:107–20
   PubMed Web of Science ®Google Scholar
• Lott D, Lehr T, Dingemanse J, et al. (2017). Impact of demographics, organ impairment, disease, formulation, and food on the pharmacokinetics of the selective S1P1 receptor modulator ponesimod based on 13 clinical studies. Clin Pharmacokinet 56:395–408
   PubMed Web of Science ®Google Scholar
• Marsolais D, Rosen H. (2009). Chemical modulators of sphingosine-1-phosphate receptors as barrier-oriented therapeutic molecules. Nat Rev Drug Discov 8:297–307
   PubMed Web of Science ®Google Scholar
• Mendoza A, Bréart B, Ramos-Perez WR, et al. (2012). The transporter Spns2 is required for secretion of lymph but not plasma sphingosine-1-phosphate. Cell Rep 2:1104–10
   PubMed Web of Science ®Google Scholar
• Montrose DC, Scherl EJ, Bosworth BP, et al. (2013). S1P1 localizes to the colonic vasculature in ulcerative colitis and maintains blood vessel integrity. J Lipid Res 54:843–51
   PubMed Web of Science ®Google Scholar
• Peyrin-Biroulet L, Morgan M, Christopher R, et al. (2016). Safety, pharmacokinetics and pharmacodynamics of etrasimod (APD334), an oral, selective S1P receptor modulator, after single dose escalation in healthy volunteers. Presented at Advances in Inflammatory Bowel Diseases Annual Meeting, December 8–10, Orlando, Florida. Available at: http://www.arenapharm.com/wp-content/uploads/2016/12/407C1DC3.pdf
   Google Scholar
• Piali L, Froidevaux S, Hess P, et al. (2011). The selective sphingosine 1-phosphate receptor 1 agonist ponesimod protects against lymphocyte-mediated tissue inflammation. J Pharmacol Exp Ther 337:547–56
   PubMed Web of Science ®Google Scholar
• Reyes M, Brossard P, Chassard D, et al. (2014b). Effects of ponesimod, a selective S1P1 receptor modulator, on the pharmacokinetics of a hormonal combination contraceptive. Eur J Clin Pharmacol 70:287–93
   PubMed Web of Science ®Google Scholar
• Reyes M, Hoch M, Brossard P, et al. (2014a). Effects of ethnicity and sex on the pharmacokinetics and pharmacodynamics of the selective sphingosine-1-phosphate receptor 1 modulator ponesimod: a clinical study in Japanese and Caucasian subjects. Pharmacology 94:223–9
   PubMed Web of Science ®Google Scholar
• Reyes M, Hoch M, Brossard P, et al. (2015). Mass balance, pharmacokinetics and metabolism of the selective S1P1 receptor modulator ponesimod in humans. Xenobiotica 45:139–49
   PubMed Web of Science ®Google Scholar
• Rivera J, Proia RL, Olivera A. (2008). The alliance of sphingosine-1-phosphate and its receptors in immunity. Nat Rev Immunol 8:753–63
   PubMed Web of Science ®Google Scholar
• Rosen H, Gc PJ, Sanna MG, et al. (2009). Sphingosine 1-phosphate receptor signaling. Annu Rev Biochem 78:743–68
   PubMed Web of Science ®Google Scholar
• Scherz MW, Brossard P, D'Ambrosio D, et al. (2015). Three different up-titration regimens of ponesimod, an S1P1 receptor modulator, in healthy subjects. J Clin Pharmacol 55:688–97
   PubMed Web of Science ®Google Scholar
• Seifert SA, Kovnat D, Anderson VE, et al. (2016). Acute hepatotoxicity associated with therapeutic doses of intravenous acetaminophen. Clin Toxicol (Phila) 54:282–5
   PubMed Web of Science ®Google Scholar
• Spiegel S, Milstien S. (2003). Sphingosine-1-phosphate: an enigmatic signalling lipid. Nat Rev Mol Cell Biol 4:397–407
   PubMed Web of Science ®Google Scholar
• Srinivas NR. (2016). Clinical drug-drug interactions of bosentan, a potent endothelial receptor antagonist, with various drugs: physiological role of enzymes and transporters. Gen Physiol Biophys 35:243–58
   PubMed Web of Science ®Google Scholar
• Srinivas NR. (2016). Influence of morbidly obesity on the clinical pharmacokinetics of various anti-infective drugs: reappraisal using recent case studies-issues, dosing implications, and considerations. Am J Ther. [Epub ahead of print]. doi: 10.1097/MJT0000000000000401
   PubMed Web of Science ®Google Scholar
• Sugahara K, Maeda Y, Shimano K, et al. (2017). Amiselimod, a novel sphingosine 1-phosphate receptor-1 modulator, has potent therapeutic efficacy for autoimmune diseases, with low bradycardia risk. Br J Pharmacol 174:15–27
   PubMed Web of Science ®Google Scholar
• Teijaro JR, Walsh KB, Cahalan S, et al. (2011). Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection. Cell 146:980–91
   PubMed Web of Science ®Google Scholar
• Valentine WJ, Godwin VI, Osborne DA, et al. (2011). FTY720 (Gilenya) phosphate selectivity of sphingosine 1-phosphate receptor subtype 1 (S1P1) G protein-coupled receptor requires motifs in intracellular loop 1 and transmembrane domain 2. J Biol Chem 286:30513–25
   PubMed Web of Science ®Google Scholar
• Xu J, Gray F, Henderson A, et al. (2014). Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers. Clin Pharmacol Drug Dev 3:170–8
   PubMed Web of Science ®Google Scholar
• You S, Piali L, Kuhn C, et al. (2013). Therapeutic use of a selective S1P1 receptor modulator ponesimod in autoimmune diabetes. PLoS One 8:e77296
   PubMed Web of Science ®Google Scholar